Will Newton
@WillNewton19Healthcare journalist covering drug pricing policy at 340B Report, Williams College ’20, #MFFL
Similar User
@Triumvirainc
@ItachoGR
@MattJPurcell
@erica_fiorini
@kevin_z_yang
@gigi_hadid_not
@ericgibblen
@johnmenton
I spent the last month writing a piece on the future of medicine in outer space! I spoke to researchers about designing drug trials on the ISS, studying how humans respond to cosmic radiation, synthesizing artificial medicine for a Mars mission, and more: clinicaltrialsarena.com/analysis/medic…
I asked Dr. Fauci about the challenges of studying long Covid in clinical trial, and heard his takes on Covid misinformation and public perception: clinicaltrialsarena.com/special-focus/…
After #ASCO22 focused on the need for more diversity in cancer clinical trials, I wrote about how experts are leveraging data to improve trial recruitment and design for @TrialsArena clinicaltrialsarena.com/analysis/diver…
There is still no specific treatment for #dengue, despite 390 million yearly infections - a number that is rising. Our #DrugDiscovery Director Charles Mowbray & other researchers reflect on how to overcome drug development obstacles. @TrialsArena #5thADS bit.ly/3mBTqjW
On International Clinical Trials Day, we have a feature on Dengue fever, on the struggle to develop antivirals and vaccines. Reporting by @WillNewton19 clinicaltrialsarena.com/analysis/dengu…
Some ultra-rare diseases have fewer than 30 known patients globally and almost no available treatments. I spoke to researchers, regulators and bioethicists on new strategies to test and approve drugs for ultra-rare conditions:
The FDA defines rare diseases as occurring in less than 200,000 people. But what happens when a disease is so rare it only exists in one person? @WillNewton19 spoke to researchers and regulators on the challenges of ultra-rare disease drug development. clinicaltrialsarena.com/analysis/drug-…
NeuroSense CEO @NoonAlon previews an upcoming Phase IIb trial in #ALS with reporter @WillNewton19 Read more about the target patient population, trial endpoints, and timeline here: clinicaltrialsarena.com/news/neurosens…
I wrote about how e-commerce pharmacies are attempting to cut soaring insulin prices, and the challenges they face, including insulin black markets: pharmaceutical-technology.com/features/insul…
Differing endpoint and efficacy expectations can make designing an ALS clinical trial challenging. @WillNewton19 talked to KOLs and found ways to damped drug development obstacles clinicaltrialsarena.com/analysis/mappi…
In an exclusive, @medicagoinc previews its blueprint for a booster trial of its Covid-19 vaccine candidate slated for January, @WillNewton19 reports #Medicago clinicaltrialsarena.com/news/company-n…
Platform trials can streamline rare disease research by testing multiple treatments & diseases under one protocol. @WillNewton19 reports on the upside and challenges of this innovative trial design, and its potential in rare dystrophies and gene therapies clinicaltrialsarena.com/features/platf…
Clinical Trials Arena's William Newton (@WillNewton19) caught up with @AnnovisBio CEO Maria Maccecchini (@MLMaccecchini). She gave us a sneak peek at the company's Phase III trial blueprint for ANVS401 in Alzheimer’s and Parkinson’s disease $ANVS clinicaltrialsarena.com/analysis/annov…
Schizophrenia drug landscape: a stagnant field on the cusp of change? @WillNewton19 talks to experts about Sunovion’s ulotaront, Minerva’s roluperidone, and Teva and MedinCell’s extended-release risperidone $SEPR $TEVA $MDCLF $NERV clinicaltrialsarena.com/analysis/schiz…
@WillNewton19 and my story on how Merck and Ridgeback’s #molnupiravir rollout will be difficult to map in an uncertain Covid-19 landscape. While the field figures out the oral antiviral's safety profile the initial emphasis may be on high-risk people clinicaltrialsarena.com/analysis/molnu… $mrk
Wrote about the incomplete safety data for Aduhelm, the recently FDA-approved Alzheimer’s disease drug bit.ly/adusafety
I wrote about how a rare Medicare process could affect uptake of the controversial Alzheimer's drug Aduhelm clinicaltrialsarena.com/analysis/aduhe…
My first @Pharma_GD not behind their paywall 👀 clinicaltrialsarena.com/comment/alkerm…
United States Trends
- 1. Hunter 974 B posts
- 2. Josh Allen 47,2 B posts
- 3. 49ers 53,3 B posts
- 4. 49ers 53,3 B posts
- 5. Niners 10,6 B posts
- 6. #BaddiesMidwest 16,2 B posts
- 7. Burisma 35 B posts
- 8. Montas 3.309 posts
- 9. Purdy 8.557 posts
- 10. Achilles 5.971 posts
- 11. Dolly 14,5 B posts
- 12. Hardy 13,7 B posts
- 13. #SFvsBUF 20,9 B posts
- 14. #RHOP 6.043 posts
- 15. AFC East 8.440 posts
- 16. Manaea N/A
- 17. #Married2Med 4.235 posts
- 18. Stearns N/A
- 19. Big Guy 61,9 B posts
- 20. #YellowstoneTV 3.083 posts
Something went wrong.
Something went wrong.